Holding pharmaceutical industry actors to account
Our legal, medical, and technical policy experts have collected examples where pharmaceutical companies are suspected of using their monopolies to charge excessive prices for their medicines. “Cases of interest” are medicines the Pharmaceutical Accountability Foundation deems worthy of research to determine if their high prices are resulting from unjust practices; under “Legal action” are cases where either the Pharmaceutical Accountability Foundation or another public health organisation has found adequate evidence of malfeasance to bring a case against the owning pharmaceutical company.
PAF also gathers and shares its legal expertise in a living guidance document for other non-governmental organisations.
Other Cases of Interest:
- mexiletine (Namuscla, message in Dutch only)
- pyrimethamine (Daraprim)
- lithium (Priadel)